Editorial comment on the use of botulinum toxin

Editorial

A P Moore. Eur J Neurol. 2012 Mar.

. 2012 Mar;19(3):357-8.

doi: 10.1111/j.1468-1331.2011.03573.x. Epub 2011 Oct 31.

No abstract available

Comment on

Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
Dressler D. Dressler D. Eur J Neurol. 2012 Mar;19(3):385-9. doi: 10.1111/j.1468-1331.2011.03559.x. Epub 2011 Oct 28. Eur J Neurol. 2012. PMID: 22035051 Review.

Editorial comment on '5 year experience with incobotulinumtoxinA (Xeomin(®) ) the first botulinum toxin drug free of complexing proteins'.
Aoki KR. Aoki KR. Eur J Neurol. 2012 Mar;19(3):355-6. doi: 10.1111/j.1468-1331.2011.03560.x. Epub 2011 Oct 15. Eur J Neurol. 2012. PMID: 21999802 No abstract available.
Botulinum toxin and human serum albumin.
Malhotra R, Huilgol SC, Selva D. Malhotra R, et al. Arch Ophthalmol. 2003 Nov;121(11):1661; discussion 1661-2. doi: 10.1001/archopht.121.11.1661-a. Arch Ophthalmol. 2003. PMID: 14609937 No abstract available.
Dysport.
Markey AC. Markey AC. Dermatol Clin. 2004 Apr;22(2):213-9. doi: 10.1016/s0733-8635(03)00022-6. Dermatol Clin. 2004. PMID: 15222582 Review.
Botulinum toxin for UES dysfunction: therapy or poison?
Ravich WJ. Ravich WJ. Dysphagia. 2001 Summer;16(3):168-70. doi: 10.1007/s00455-001-0060-1. Dysphagia. 2001. PMID: 11453561 No abstract available.
Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications.
de Almeida AT, De Boulle K. de Almeida AT, et al. J Cosmet Laser Ther. 2007;9 Suppl 1:17-22. doi: 10.1080/17429590701523794. J Cosmet Laser Ther. 2007. PMID: 17885882 Review.